Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.
Activation of the c-erbB-2 oncogene can occur by amplification of c-erbB-2 DNA and by overproduction of c-erbB-2 mRNA and c-erbB-2 protein. Approximately 20 percent of breast carcinomas show evidence of c-erbB-2 activation, which correlates with a poor prognosis primarily in patients with metastasis to axillary lymph nodes. Studies that have attempted to correlate c-erbB-2 activation with other prognostic factors in breast carcinoma have reported conflicting conclusions. The pathologic and clinical significance of c-erbB-2 activation in other neoplasms is unclear and should be assessed by additional studies.
T P
TP
Singleton
J G
JG
Strickler
D001943:Breast Neoplasms / Q000235:genetics*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000235:genetics; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D005833:Genital Neoplasms, Female / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D011519:Proto-Oncogenes; D018719:Erb-b2 Receptor Tyrosine Kinases
D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases